Axsome resolved litigation with a rival pharmaceutical company, protecting one of Axsome's key drugs. The settlement protects Axsome's revenue stream for more than a decade. Axsome, maker of the ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was up as much as 5.6% earlier in the day. The jump comes as the S&P 500 ...

Axsome Therapeutics has resolved the patent infringement lawsuit that it filed against Teva Pharmaceutical Industries after the generics powerhouse sought FDA approval for a copycat to Axsome's ...

Axsome, maker of the antidepressant Auvelity, reached a settlement with fellow drugmaker Teva Pharmaceuticals. The latter, which specializes in generic drugs, had submitted an Abbreviated New Drug ...

Analysts across Wall Street raised their price targets for Axsome. The upgrades came after news broke that the company had settled a key lawsuit. A senior analyst at the Japanese banking giant ...

Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's ...

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Teva Pharmaceuticals (TEVA) resolving all patent litigation related to Axsome’s AUVELITY product. The ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $143. ...

Deutsche Bank analyst David Hoang initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $176 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help ...